Abstract
Objectives
On a background of the rapidly expanding clinical use of ketamine and esketamine for treatment of depression and other conditions, we examined safety monitoring, seeking to identify knowledge gaps relevant to clinical practice.
Methods
An international group of psychiatrists discussed the issue of safety of ketamine and esketamine and came to a consensus on key safety gaps.
Results
There is no standard safety monitoring for off-label generic ketamine. For intranasal esketamine, each jurisdiction providing regulatory approval may specify monitoring. Treatment is often provided beyond the period for which safety has been demonstrated, with no agreed framework for monitoring of longer term side-effects for either generic ketamine or intranasal esketamine.
Limitations
The KSET has established face and content validity, however it has not been validated against other measures of safety.
Conclusions
We recommend the Ketamine Side Effect Tool (KSET) as a comprehensive safety monitoring tool for acute and longer term side-effects.